F2 and cancer: The combined genotypes of FVL and prothrombin G20210A, particularly in heterozygous carriers, have also been widely associated with higher risk of thromboembolic episodes while the risk of VTE increases with the number of prothrombotic alleles both in individuals with and without cancer, and the presence of thrombotic risk and cancer alleles leads to a 17-fold higher risk of VTE compared to individuals with a free history of cancer [21].